ZA200610473B - A delivery system - Google Patents
A delivery system Download PDFInfo
- Publication number
- ZA200610473B ZA200610473B ZA200610473A ZA200610473A ZA200610473B ZA 200610473 B ZA200610473 B ZA 200610473B ZA 200610473 A ZA200610473 A ZA 200610473A ZA 200610473 A ZA200610473 A ZA 200610473A ZA 200610473 B ZA200610473 B ZA 200610473B
- Authority
- ZA
- South Africa
- Prior art keywords
- membrane
- core
- active agent
- therapeutically active
- delivery system
- Prior art date
Links
- 239000013543 active substance Substances 0.000 claims abstract description 136
- 239000012528 membrane Substances 0.000 claims abstract description 105
- 239000000806 elastomer Substances 0.000 claims abstract description 56
- 229920001971 elastomer Polymers 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 230000001105 regulatory effect Effects 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000001276 controlling effect Effects 0.000 claims abstract description 12
- 210000004379 membrane Anatomy 0.000 claims description 101
- 229920000858 Cyclodextrin Polymers 0.000 claims description 46
- 239000007943 implant Substances 0.000 claims description 30
- 229940097362 cyclodextrins Drugs 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 claims 1
- 239000011162 core material Substances 0.000 description 77
- 239000011159 matrix material Substances 0.000 description 18
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- -1 hydroxypropyl Chemical group 0.000 description 15
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 4
- 229960005352 gestodene Drugs 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000708 anti-progestin effect Effects 0.000 description 2
- 239000003418 antiprogestin Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VHZPUDNSVGRVMB-RXDLHWJPSA-N (8s,11r,13s,14s,17s)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(C(=O)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)C(F)(F)C(F)(F)F)[C@]2(C)C1 VHZPUDNSVGRVMB-RXDLHWJPSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010022528 Interactions Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000490025 Schefflera digitata Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000004695 complexes Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Communication Control (AREA)
- Adjustment And Processing Of Grains (AREA)
- Vending Machines For Individual Products (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Selective Calling Equipment (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04396049A EP1629844B2 (en) | 2004-07-13 | 2004-07-13 | A longterm delivery system with controlled initial burst |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200610473B true ZA200610473B (en) | 2008-06-25 |
Family
ID=34932022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200610473A ZA200610473B (en) | 2004-07-13 | 2005-07-05 | A delivery system |
Country Status (24)
Country | Link |
---|---|
US (1) | US7850986B2 (pt) |
EP (1) | EP1629844B2 (pt) |
JP (1) | JP4881861B2 (pt) |
KR (1) | KR20070035032A (pt) |
CN (1) | CN1984639A (pt) |
AT (1) | ATE372772T1 (pt) |
AU (1) | AU2005261682B2 (pt) |
BR (1) | BRPI0513295A (pt) |
CA (1) | CA2569542C (pt) |
DE (1) | DE602004008912T3 (pt) |
DK (1) | DK1629844T4 (pt) |
ES (1) | ES2293193T5 (pt) |
HK (1) | HK1086751A1 (pt) |
IL (1) | IL179846A (pt) |
MX (1) | MX2007000433A (pt) |
NO (1) | NO334931B1 (pt) |
NZ (1) | NZ551823A (pt) |
PL (1) | PL1629844T5 (pt) |
PT (1) | PT1629844E (pt) |
RU (1) | RU2412693C2 (pt) |
SI (1) | SI1629844T1 (pt) |
UA (1) | UA91337C2 (pt) |
WO (1) | WO2006005794A1 (pt) |
ZA (1) | ZA200610473B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1629844E (pt) | 2004-07-13 | 2007-10-17 | Bayer Schering Pharma Oy | Sistema de distribuição a longo prazo com distribuição súbita inicial controlada |
US8541028B2 (en) * | 2004-08-04 | 2013-09-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
US20100158980A1 (en) * | 2008-12-18 | 2010-06-24 | Casey Kopczynski | Drug delivery devices for delivery of therapeutic agents |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
MX357598B (es) * | 2011-07-20 | 2018-07-16 | F Kiser Patrick | Dispositivos intravaginales para administración de fármaco. |
WO2013110008A1 (en) | 2012-01-18 | 2013-07-25 | Worldwide Innovative Healthcare, Inc. | Modifiable occlusive skin dressing |
AR089765A1 (es) | 2012-01-23 | 2014-09-17 | Bayer Oy | Un sistema para el suministro de un farmaco |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
CN105310974B (zh) * | 2014-08-01 | 2019-08-23 | 山东绿叶制药有限公司 | 罗替戈汀及其衍生物或其药用盐的植入剂 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832252A (en) | 1970-09-29 | 1974-08-27 | T Higuchi | Method of making a drug-delivery device |
NZ217844A (en) | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
ES2054784T3 (es) † | 1987-08-08 | 1994-08-16 | Akzo Nv | Un metodo para la fabricacion de un implante. |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
RU2088166C1 (ru) | 1993-08-10 | 1997-08-27 | Педдер Валерий Викторович | Способ контрацепции и устройство для его осуществления |
DE69534780T2 (de) | 1994-04-08 | 2006-10-05 | Qlt Usa Inc., Fort Collins | Flüssige Zusammensetzungen zur Arzneistoffabgabe |
US5492947A (en) * | 1994-06-23 | 1996-02-20 | Aspen Research Corporation | Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative |
GB2290964A (en) | 1994-07-08 | 1996-01-17 | Arto Olavi Urtti | Transdermal drug delivery system |
FI97947C (fi) | 1994-09-27 | 1997-03-25 | Leiras Oy | Menetelmä lääkepreparaatin valmistamiseksi |
GB9522403D0 (en) † | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
US6416778B1 (en) * | 1997-01-24 | 2002-07-09 | Femmepharma | Pharmaceutical preparations and methods for their regional administration |
US6039968A (en) * | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
NZ330596A (en) * | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
WO1999061062A1 (en) † | 1998-05-29 | 1999-12-02 | Massachusetts Institute Of Technology | Cyclodextrin complexes |
AU6517900A (en) | 1999-08-03 | 2001-02-19 | Smith & Nephew, Inc. | Controlled release implantable devices |
AU2001237221A1 (en) * | 2000-01-11 | 2001-07-24 | Roland Bodmeier | Implants, particles |
US6299894B1 (en) | 2000-05-10 | 2001-10-09 | Leiras Oy | Drug delivery device, especially for the delivery of gestodene |
AU2002210580A1 (en) | 2000-10-20 | 2002-04-29 | Leiras Oy | Drug delivery system |
US6951654B2 (en) | 2001-03-27 | 2005-10-04 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
CN1210079C (zh) | 2001-04-25 | 2005-07-13 | 上海市计划生育科学研究所 | 阴道环制剂及其应用 |
JP2005503389A (ja) * | 2001-08-31 | 2005-02-03 | シエーリング オサケユイチア | 薬物送達システム |
US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
US20070043332A1 (en) † | 2003-07-10 | 2007-02-22 | Galen (Chemiclas) Liimited | Intravaginal drug delivery devices |
MXPA06010905A (es) † | 2004-03-24 | 2007-03-08 | Organon Nv | Sistema para el suministro de farmacos basados en copolimeros de polietileno y acetato de vinilo. |
PT1629844E (pt) | 2004-07-13 | 2007-10-17 | Bayer Schering Pharma Oy | Sistema de distribuição a longo prazo com distribuição súbita inicial controlada |
-
2004
- 2004-07-13 PT PT04396049T patent/PT1629844E/pt unknown
- 2004-07-13 ES ES04396049T patent/ES2293193T5/es active Active
- 2004-07-13 SI SI200430465T patent/SI1629844T1/sl unknown
- 2004-07-13 DE DE602004008912T patent/DE602004008912T3/de active Active
- 2004-07-13 AT AT04396049T patent/ATE372772T1/de active
- 2004-07-13 EP EP04396049A patent/EP1629844B2/en active Active
- 2004-07-13 DK DK04396049.1T patent/DK1629844T4/da active
- 2004-07-13 PL PL04396049T patent/PL1629844T5/pl unknown
-
2005
- 2005-05-07 UA UAA200613637A patent/UA91337C2/ru unknown
- 2005-07-05 RU RU2006145900/15A patent/RU2412693C2/ru not_active IP Right Cessation
- 2005-07-05 NZ NZ551823A patent/NZ551823A/en not_active IP Right Cessation
- 2005-07-05 MX MX2007000433A patent/MX2007000433A/es active IP Right Grant
- 2005-07-05 CN CNA2005800232239A patent/CN1984639A/zh active Pending
- 2005-07-05 WO PCT/FI2005/000314 patent/WO2006005794A1/en active Application Filing
- 2005-07-05 US US11/631,873 patent/US7850986B2/en not_active Expired - Fee Related
- 2005-07-05 AU AU2005261682A patent/AU2005261682B2/en not_active Ceased
- 2005-07-05 KR KR1020077000571A patent/KR20070035032A/ko not_active Application Discontinuation
- 2005-07-05 ZA ZA200610473A patent/ZA200610473B/en unknown
- 2005-07-05 JP JP2007520845A patent/JP4881861B2/ja not_active Expired - Fee Related
- 2005-07-05 CA CA2569542A patent/CA2569542C/en not_active Expired - Fee Related
- 2005-07-05 BR BRPI0513295-9A patent/BRPI0513295A/pt not_active IP Right Cessation
-
2006
- 2006-06-16 HK HK06106904A patent/HK1086751A1/xx not_active IP Right Cessation
- 2006-12-05 IL IL179846A patent/IL179846A/en not_active IP Right Cessation
-
2007
- 2007-02-12 NO NO20070805A patent/NO334931B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2569542C (en) | A delivery system | |
AU741482B2 (en) | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors | |
KR100616759B1 (ko) | 중합체성 미세다공성 필름이 피복된 피하 이식물 | |
US5035891A (en) | Controlled release subcutaneous implant | |
JP2009268915A (ja) | ゼロ次長期放出同軸インプラント | |
CZ110298A3 (cs) | Systém pro aplikaci účinných látek | |
IE62505B1 (en) | Biodegradable implant | |
KR20010006027A (ko) | 방광내 약물 송달 시스템 | |
EP1150630A1 (en) | Prolonged release bioadhesive vaginal gel dosage form | |
JP2008523131A (ja) | 動物用インサイチュ成形インプラント | |
JPH08506318A (ja) | ノメゲストロール誘導体に基づく皮下埋め込み物 | |
CA2861947A1 (en) | A drug delivery system | |
DE2247949A1 (de) | Einrichtung zur verabreichung von arneimitteln | |
AU2007324467A1 (en) | Vaginal delivery system for mirtazapine | |
WO2010133757A1 (en) | Vaginal delivery system | |
EP2062569B1 (en) | Vaginal delivery system | |
WO1992018101A1 (en) | Vaginal drug delivery device | |
EP4215180A1 (en) | A drug delivery system |